

## Challenge with hyperosmolar mannitol induces mast cell activation in isolated human small airways: a model of exercise-induced bronchoconstriction

**BACKGROUND:** Exercise-induced bronchoconstriction (EIB) is believed to occur by loss of water from the airway lining fluid causing a local increase of osmolarity that triggers mast cell activation. This can be mimicked in patients by inhalation of mannitol. The mechanism involved, however, remains unclear.

**AIM:** Our aim was to develop a model using isolated human bronchi in order to study the effect of hyperosmolar bronchoconstriction.

**METHODS:** Small bronchi (inner diameter of 0.5-2 mm) were isolated from macroscopically healthy human lung tissue specimens obtained from patients undergoing surgery (n=23). The segment were incubated overnight and mounted in a tissue organ bath to measure smooth muscle contractions evoked by challenge with hyperosmolar mannitol in relation to contractions generated by 60 mMof potassium chloride.

**RESULTS:** A protocol was developed to investigate hyperosmolar mannitol-induced bronchoconstriction ( $E_{max}$ :  $43.0 \pm 3.2\%$ ). The constriction could be completely prevented using a combination of receptor antagonists blocking the TP, H<sub>1</sub> and CysLT<sub>1</sub> receptors (SQ-29,548, mepyramine and montelukast, respectively;  $p < 0.05$ ), or by pretreatment with the mast cell stabilizer cromolyn (100  $\mu$ M). In contrast, global inhibition of the cyclooxygenase enzymes using indomethacin enhanced the bronchoconstriction ( $E_{max}$ :  $65.6 \pm 5.6\%$ ;  $p < 0.05$ ). Likewise, treatment with either EP<sub>2</sub> (PF-04418948) or EP<sub>4</sub> (ONO-AE3-208) receptor antagonists also enhanced the mannitol-induced bronchoconstriction ( $E_{max}$ :  $67.4 \pm 5.2$  and  $66.0 \pm 4.0$ , respectively;  $p < 0.05$ ).

**CONCLUSION:** When isolated human bronchi are exposed to mannitol a bronchoconstriction occurs that is mediated by release of typical mast cell mediators. The increased effect during cyclooxygenase inhibition suggests a production of prostanoids that counteracts the mannitol-induced bronchoconstriction. These prostanoids acts on both EP<sub>2</sub> and EP<sub>4</sub> receptors possibly inducing both mast cell inhibition and bronchorelaxation, as observed previously for exogenous PGE<sub>2</sub> (1). This first *ex vivo* protocol of hyperosmolar mast cell activation in isolated human bronchi can be used for further mechanistic studies of EIB.

1. Säfholm J. et al. (2015) J Allergy Clin Immunol. doi: 10.1016/j.jaci.2015.04.002